180 Life Sciences Corp: A Bold Pivot to Crypto with a $425 Million Ethereum Treasury
In a surprising turn of events, 180 Life Sciences Corp, a biotech company known for its focus on developing novel drugs for inflammatory conditions, has announced a significant strategic shift. The company, which trades on the Nasdaq under the ticker ATNF, is transitioning from its traditional biotech roots to embrace the burgeoning world of cryptocurrency. This pivot is underscored by a substantial $425 million private placement aimed at establishing an Ethereum treasury, marking a new chapter for the company as it rebrands to ETHZilla.
A Strategic Shift Amidst Financial Challenges
The decision to pivot comes at a time when 180 Life Sciences has faced considerable financial challenges. The company’s stock has seen a dramatic decline, with its close price on July 30, 2025, standing at $3.28, a far cry from its 52-week high of $17.75 in October 2024. The market capitalization currently sits at $12.86 million, reflecting the volatility and challenges the company has faced in the biotech sector.
The $425 Million Ethereum Treasury Initiative
The $425 million private placement is a cornerstone of 180 Life Sciences’ new strategy. The funds will be used to establish an Ethereum treasury, a move that aligns the company with the growing trend of integrating blockchain technology into traditional business models. This initiative is led by a consortium of digital asset leaders and is part of a broader plan to rebrand the company as ETHZilla.
The private placement was executed at $2.65 per share, with participation from over 60 investors, highlighting significant interest and confidence in the company’s new direction. This strategic move is not just about diversifying the company’s portfolio but also about positioning itself at the forefront of the digital asset revolution.
Rebranding to ETHZilla
The rebranding to ETHZilla is symbolic of the company’s commitment to its new path. The name change reflects a bold and dynamic approach to the cryptocurrency market, signaling a departure from its previous identity as a biotech firm. This rebranding is part of a larger strategy to launch a next-generation Ethereum treasury, which aims to generate yield and capitalize on the growing demand for digital assets.
Industry Reaction and Future Prospects
The pivot has garnered attention across financial and cryptocurrency news platforms, with many analysts viewing it as a bold and innovative move. The transition from biotech to crypto is seen as a strategic gamble, but one that could potentially pay off if the cryptocurrency market continues its upward trajectory.
As 180 Life Sciences embarks on this new journey, the company faces both opportunities and challenges. The success of its Ethereum treasury strategy will depend on market conditions, regulatory developments, and the company’s ability to execute its plans effectively. However, if successful, this pivot could redefine the company’s future and set a precedent for other firms considering similar transitions.
In conclusion, 180 Life Sciences Corp’s shift to cryptocurrency with a $425 million Ethereum treasury marks a significant transformation. As ETHZilla, the company aims to leverage the potential of digital assets, navigating the complexities of the crypto market while leaving its biotech legacy behind. The coming months will be crucial in determining whether this bold move will lead to a new era of success for the company.